ReviewClinical ophthalmology (Auckland, N.Z.)2026
Strategies for the Prevention and Control of Complications of Pathological Myopia: A Systematic Review of Research Progress from Axial Control to Target Organ Protection.
Review in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pathological myopia (PM) is one of the leading causes of irreversible vision impairment and blindness worldwide, characterized by progressive excessive elongation of the eyeball and a series of fundus complications, posing a serious threat to visual health. This review systematically analyzes the evolution and progress of prevention and control strategies for complications in this field based on the latest research literature from 2021 to 2025. The current prevention and control concept has evolved from simply controlling axial elongation to emphasizing comprehensive protection of target organs such as the retina, choroid, and optic nerve. This review provides an in-depth analysis of the latest evidence and efficacy of pharmacological interventions (such as low-concentration atropine), optical interventions (such as specially designed frame glasses and orthokeratology lenses), behavioral interventions, and emerging targeted treatments (such as anti-VEGF drugs and gene therapy) in delaying axial elongation and preventing complications. It also explores the crucial role of multimodal imaging assessment and artificial intelligence risk prediction models in developing personalized prevention and control plans, and looks ahead to future research directions for achieving integrated management from "axial control" to "target protection", aiming to provide evidence-based support for clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.